News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Egetis recruits Desiree Luthman as Vice President Global Regulatory Affairs

November 7, 2023

Stockholm, Sweden, November 7, 2023. Egetis Therapeutics AB (publ) (Nasdaq Stockholm: EGTX) today announced the recruitment of Desiree Luthman, as Vice President Global Regulatory Affairs, effective November 13, 2023. Desiree will be a member of the Company’s Executive Leadership Team, and report to the CEO Nicklas Westerholm. She is based in Doylestown, Pennsylvania, USA.

Desiree has over 25 years of pharmaceutical industry experience in Global Regulatory Affairs and have successfully contributed to both FDA and EMA approvals of new drugs. Her extensive experience includes strategic regulatory responsibility covering non-clinical development, phase I-III clinical phase programs for CNS disorders, pain, inflammation, immunology, respiratory, metabolic as well as rare diseases. She has led numerous regulatory affairs teams focusing on a variety of modalities, including small molecules, biologics and gene therapy.

Prior to joining Egetis, Desiree was Senior Vice President Regulatory Affairs at Passage Bio, a US-based gene therapy company. Before that she had executive and senior regulatory affairs leadership positions at Verona Pharma, Sanofi, BMS, Celgene, Xytis and AstraZeneca. Desiree trained and practiced as a dentist before joining the pharmaceutical industry.
Nicklas Westerholm, CEO of Egetis, commented:I’m delighted to welcome Desiree to Egetis and proud that we have been able to attract such a talented and experienced global regulatory affairs leader to our Company. Desiree’s experience in successfully leading projects to regulatory approvals with the FDA and EMA makes her ideal in the role as VP Global Regulatory Affairs at Egetis. Her global strategic regulatory affairs background will be invaluable as we embark on a truly transformational period at Egetis, with our lead investigational product Emcitate currently under review by the EMA and with the expected FDA filing in 2024.”



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10